ARTICLE SUMMARY:
CMS official outlines key role of fit-for-purpose studies as part of agency’s forthcoming TCET pathway with specific guidance in the works.
At the recent San Francisco MedTech Strategist Innovation Summit in November, Steve Farmer, MD, PhD, chief strategy officer of CMS’ Coverage and Analysis Group in the Center for Clinical Standards and Quality, participated on a panel on medtech reimbursement and provided an update on the goals and status of the Transitional Coverage for Emerging Technologies (TCET) program. (TCET being the successor program, if you will, to the Medicare Coverage of Innovative Technology [MCIT] plan that was implemented in the closing days of the Trump administration, only to be repealed by President Biden shortly after taking office. CMS published a proposal on June 22 of this year open for public comments, which Farmer noted, prompted a large number of responses that the agency is in the process of reviewing.
